2000
DOI: 10.1007/978-1-4757-4580-1_22
|View full text |Cite
|
Sign up to set email alerts
|

Vaccines against Intracellular Pathogens

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0
1

Year Published

2001
2001
2006
2006

Publication Types

Select...
4
1

Relationship

2
3

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 144 publications
0
3
0
1
Order By: Relevance
“…Improved animal models would greatly facilitate studies focusing on mycobacterial pathogenesis and vaccines (9,35).…”
Section: Discussionmentioning
confidence: 99%
“…Improved animal models would greatly facilitate studies focusing on mycobacterial pathogenesis and vaccines (9,35).…”
Section: Discussionmentioning
confidence: 99%
“…The class II haplotypes are indicated using the D-region haplotype nomenclature (16,42,47,53). The official allele names assigned by the Bovine Leukocyte Antigen Nomenclature Committee of the International Society for Animal Genetics were used for the class II alleles present in each haplotype (14,54 For analysis of the composition of peripheral blood at the initiation of culture, 10 ml of blood was collected in ACD and lysed in Tris-buffered NH 4 Cl to remove erythrocytes. The resultant cells were washed several times in phosphate-buffered saline (PBS) containing 20% ACD (PBS-ACD) to remove excess platelets and then used in FC as described elsewhere (18).…”
Section: Methodsmentioning
confidence: 99%
“…It causes significant economic loss to producers, especially the dairy industry, due to increase in forage consumption, decreased milk production, and early culling due to poor health of affected animals (reviewed in reference 51). The disease has been difficult to control because of the lack of sensitivity and specificity of available diagnostic assays (5) and the lack of an efficacious vaccine (4,33,37). Available assays, such as M. avium subsp.…”
mentioning
confidence: 99%
“…Idealmente, también la inactivación de genes deberá generar cepas que sean compatibles con pruebas diagnósticas y que permitan una rápida y eficaz diferenciación entre individuos vacunados e infectados. Además, las cepas atenuadas deberán ser productos finales carentes de marcadores, principalmente marcadores que confieran resistencia a agentes quimioterapéuticos, para evitar la transferencia de estos genes a los aislamientos clínicos (141).…”
Section: Consideraciones Finalesunclassified